

FOR IMMEDIATE RELEASE

Theralase Laser Technologies Announces Q2 Financials

Toronto, Ontario – August 31, 2010 Theralase Technologies Inc. (TSX-V: TLT) announces its second quarter 2010 financials.

Revenue increased by 2% year over year with total revenue for three months ending June 30, 2010 at \$640,270, compared to \$629,004 for the same period in 2009.

Selling expenses increased by 7% for the three month period ending June 30, 2010, represented as 25% of product sales compared with 18% for the same period the previous year. The percentage increase is due to increased spending on travel and advertising.

A 15% increase in administrative expenses (\$350,980) represents increased expenditures on stock-based compensations and salaries (recent hires – production and accounting).

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated, “The net loss for the period ended June 30, 2010 was \$198,533, which included \$82,036 of non-cash expenses (amortization, stock-based compensation expense, foreign exchange gain/loss and lease inducements). The company expends the future product development costs of the TLC-2000 Biofeedback Therapeutic Laser and TLC-3000 Photo Dynamic Compound Technology from existing TLC-1000 Therapeutic Laser product sales, resulting in the overall net loss. The Company is poised for significant growth in the 3rd half of 2010 and 2011 as the Company expands its sales and marketing efforts in the US and internationally, and also prepares for the launch of its patented TLC-2000 Biofeedback Therapeutic Laser in 1Q2011.”

The complete consolidated financial statements and MD&A for six months ending June 30, 2010 can be found at www.theralase.com and www.sedar.com.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology used in bio-stimulation and bio-destruction applications. The technology is popularized for its efficacious treatment of chronic pain, inflammation, wound care and the ability to attack specifically targeted cancer, bacteria, and viruses when used in the presence of the Company’s patented Photodynamic Compounds.

For further information, please contact:

Roger Dumoulin-White
President & CEO
Phone: (416) 447-8455 x 225
e-mail: rwhite@theralase.com

Kristina Hachey
Chief Financial Officer
Phone: (416) 447-8455 x 224
e-mail: khachey@theralase.com

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.